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Abstract
Neo-tanshinlactone (1) and its previously reported analogs, such as 2, are potent and selective in
vitro anti-breast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps,
with a better overall yield. Structure–activity relationships studies on these compounds revealed some
key molecular determinants for this family of anti-breast agents. Several derivatives (19-21 and 24)
exerted potent and selective anti-breast cancer activity with IC50 values of 0.3, 0.2, 0.1 and 0.1 μg/
mL, respectively, against the ZR-75-1 cell lines. Compound 24 was two- to three-fold more potent
than 1 against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times
more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-
BR-3/MCF-7 selectivity. In addition, analog 2 showed potent activity against a ZR-75-1 xenograft
model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer
cell line compared with normal breast tissue-derived cell lines. Further development of lead
compounds 19-21 and 24 as clinical trial candidates is warranted.
Introduction
Historically, natural products have been the most significant source of drugs and drug leads,
which have led to numerous clinically used medicines.1-4 Accordingly, our group is interested
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in the discovery and development of novel anticancer drugs from natural plants. Drug discovery
from medicinal plants has played an important role in the treatment of cancer, and about 74%
of anticancer compounds are either natural products or natural product-derived.5 Worldwide,
over ten million new cases of cancer (all types, excluding non-melanoma skin) and over six
million deaths were estimated to occur in the year 2000.6 More than 1 million women are
diagnosed with breast cancer every year, accounting for 10% of all new cancers and 23% of
all female cancer cases.7 The disease accounts for 40,000 deaths each year in the United States
alone.8 Tamoxifen (TAM, Figure 1) is the most widely used selective estrogen receptor
modulator (SERM) for the treatment of breast cancer.9 Other drugs, including
cyclophosphamide, doxorubicin (adriamycin), and paclitaxel (taxol), are also recommended
to be used in combination in early breast cancer.8 Although the death rate from breast cancer
has declined significantly because of earlier detection and more effective treatments, toxic side
effects, low tumor selectivity, and multidrug resistance with cancer chemotherapy still prompt
the development of novel potent anti-breast cancer agents.10
Tanshen, the rhizome of Salvia miltiorrhiza Bunge, is used primarily in traditional Chinese
medicine (TCM) for the treatment of coronary heart diseases, inflammatory diseases, and
chronic hepatitis. Many biologically active constituents, including neo-tanshinlactone,
tanshinone I, and tanshinone IIA, which have been studied extensively as anticancer agents,
were first isolated from the roots of Salvia miltiorrhiza.11 Neo-tanshinlactone (1) (Figure 1),
a minor component isolated from an EtOH extract of S. miltiorrhiza, showed significant
selective in vitro anti-breast cancer activity as compared to TAM. Specifically, it was 10-fold
more potent and 20-fold more selective than TAM against ER+ and HER2++ breast cancer
cells.12 Compound 2 (Figure 1), a congener of 1, was about twice as active against MCF-7 and
SK-BR-3 cell lines as 1.13 Compound 2 was effective against approximately 40% of human
breast cancer cell lines and ineffective against other cell lines tested (total 29 cell lines,
unpublished data). Furthermore, preliminary in vivo evaluation in mice models suggested that
2 is a potent and selective anti-breast cancer agent. In both BRCA1/p53 and wild-type mice
treated with 2, mammary gland side branching was dramatically reduced (unpublished data).
In addition, 2 significantly suppressed several important protein kinases including CK2α1,
ABL, and AKT1 (Table 3 in supporting information). Mechanism of action studies are ongoing
and will be reported in due course.
Preliminary structure-activity relationships (SAR) showed that a methylated furan ring-D and
the C-4 substituent in ring A are critical for anti-breast cancer activity.13, 14 These promising
results encouraged us to continue the modification of this series to develop novel anticancer
drug candidates. To increase the chemical availability, we also optimized the synthetic
pathway. In this paper, we describe further modifications of the A-, B-, C- and D-rings, as well
as biological evaluation of newly synthesized analogs against several human cancer cell lines,
including MCF-7 (estrogen receptor positive, luminal-like breast cancer), SK-BR-3 (estrogen
receptor negative, HER2 over-expressing luminal-like breast cancer), ZR-75-1 (estrogen
receptor positive, HER2 over-expressing luminal-like breast cancer), MDA MB-231 (estrogen
receptor negative, basal cell-like breast cancer), A549 (human lung cancer), DU145 (prostate
cancer), KB (nasopharyngeal carcinoma), and KB-vin (vincristine-resistant KB subline).
Design
Our general goals in drug design are to optimize the synthesis of active analogs, systematically
explore SAR, and develop new more potent lead compounds. Thus, our first goal in this study
was to optimize the synthetic route to 2. We aimed to reduce the number of steps and increase
yields. The optimized synthetic route would then be applied to synthesize new analogs.
Secondly, synthetic modifications of 1 were considered, because the resulting fundamental
chemical and physical changes may affect molecular shapes, bond angles, and partition
Dong et al. Page 2













coefficients. Different substituents can have different hydrophobic interactions, sizes, and
electrostatic effects that can influence interaction of a ligand with its target receptors. For our
1-analogs, we reported previously that a C-4 substituent in ring-A is critical for anti-breast
cancer activity.13 Thus, compounds 19-27 with substituents of different sizes and electrostatic
properties were designed to find optimal groups at this position. In the B-ring, we changed the
phenyl ring to a pyridinone ring in 32 and 33 to explore a ring system effect. The strategy of
bioisoteric replacement can be a powerful and highly productive tool in analog design. Based
on this concept, the oxygens in ring-C were changed to sulfur and nitrogen (38-39 and
40-42). Compounds with different substituents on the furan D-ring (44-53) were also designed.
Moreover, the degree of saturation (number of double bonds) can change the orientation of a
molecule and affect its in vitro activity and selectivity. Consequently, we designed 54 and
55 to have a more saturated dihydrofuran ring-D. Finally, the furan D-ring was changed to a
substituted phenyl ring in 58 to examine the ring system effect and interaction volume.
Chemistry
Synthesis of analog 2 was achieved in five steps and an overall yield of 18%, compared with
seven steps and 3% yield reported before12,13 (Scheme 1). A Grignard reaction of 4 in the
presence of zinc chloride gave 5 in an improved yield of 85%.15 Addition of zinc chloride
increased the yield more than 25%. Analog 6 was obtained in one step, by oxidation of 5 with
Pd/C, rather than the prior two steps (hydrochloric acid and Pd/C).13 Demethylation of 6 with
boron tribromide gave naphthol 7. Treatment of 7 with polyphosphoric acid (PPA) in the
presence of 85% P2O5 and malonic acid produced 13 in 53% yield. Phosphorus pentoxide was
used to remove water from the reaction system, and its use increased the yield and
reproducibility. Finally, analog 2 was obtained via a tandem alkylation/intramolecular Aldol
reaction with an optimized procedure (70% yield),14 which increased the yield in this step by
around 20%. This overall optimized synthetic route can be applied to synthesize new analogues
and produce 2 in large scale for animal testing.
Using the optimized synthetic pathway, target compounds 19-23 were prepared from various
substituted 1-naphthols (8-12), as shown in Scheme 1. Treating naphthols 8-12 with malonic
acid in the presence of PPA (85%P2O5) provided benzochromenones 14-18, which were
converted to target compounds 19-23 under the same conditions as for synthesis of 2.16
Compound 24 was obtained by treatment of 2 with N-bromosuccinimide (NBS) and dibenzoyl
peroxide.17 Removal of the methyl group of 21 with boron tribromide afforded 25, which was
esterified with acetic anhydride and alkylated with 2-chloro-N,N-dimethylethanamine under
basic conditions to give 26 and 27, respectively.
B-ring modification was achieved through a two-step reaction sequence. Commercially
available substituted anilines 28 and 29 were reacted with diethyl malonate at 220 °C for 8 h
to give intermediates 30 and 31 (Scheme 2). The desired compounds 32 and 33 were obtained
through the tandem alkylation/intramolecular Aldol reaction described above and shown in
Scheme 1. Target compounds 38 and 39, which are bio-isosteres of 3, were obtained by using
the same two synthetic steps shown in Scheme 1 for 2 from naphthol 7, except that the starting
materials were naphthalene-1-thiol 34 and naphthalen-1-amine 35 (Scheme 3). Compounds
3 and 2 were converted to thiolactones 40 and 41, respectively, using Lawesson's reagent.18
Compound 42 was obtained by treatment of 41 with sodium acetate and hydroxylamine
hydrochloride.19
Target compounds 45-53 with various substituents on the D-ring were synthesized with the
same tandem alkylation/intramolecular Aldol reaction using different bromoketones (Scheme
4). Reduction of 3 and 2 with palladium acetate, triethyl amine, and formic acid20 afforded
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54 and 55, respectively. Compound 58 was obtained from 56 by using esterification21 and
Heck reactions.22
Results and Discussion
Together with 1 and previously reported analogs 2 and 3, the newly synthesized analogs
(19-27, 32-33, 37-38, 40-42, 45-53, 54-55, and 58) were evaluated for in vitro anti-breast cancer
activity against two human tumor cell lines: MCF-7 (ER+) and SK-BR-3 (HER2+).
Compounds that had ED50 values less than 4 μg/mL were also examined against ZR-75-1 (ER
+, HER2+) and MDAMB-231 (ER−) breast cancer cell lines (Table 1).
Initially, we investigated the effects of substitutions around the skeleton of 1 by comparing
1-3 with 19-27. The compounds displayed different degrees of activity and selectivity toward
the four breast cancer cell lines.
Against the MCF-7 cell line, small alkyl groups were favored relative to other groups at C-4
on ring-A. Analog 2, which has a C-4 ethyl group, was the most potent compound among those
tested against MCF-7. Its ED50 (0.2 μg/mL) was slightly better than that (0.6 μg/mL) of 1,
which has a C-4 methyl group. The rank order of potency for all C-4 substituted analogs was
2 (Et) > 1 (Me) > 20 (Pr) = 19 (i-Pr) > 21 (OMe) > 3 (H) > 23 (F) > 27 (dimethylamino) >
26 (OAc) > 25 (OH) > 22 (OEt). The substituents on the furan (ring-D) double bond were also
investigated. A methyl group (2) was better than either an ethyl (47) or methoxyphenyl (53)
group at the R2 position. However, at the R3 position, a methyl group was distinctly disfavored
(48-51). These results indicated that the optimal combination on ring-D was methyl at R2 and
hydrogen at R3.
Most compounds were equipotent or more potent against SK-BR-3 compared with MCF-7
cells. Compounds 2 and 1 were even more potent against SK-BR-3, with ED50 values of 0.1
and 0.2 μg/mL, respectively. However, 20 and 24 (4-bromoethyl) were also equipotent to 2,
and 19 was equipotent to 1 against this cell line. Compounds 3, 23, 19, and 22 showed good
but lower activity (ED50 1.0, 1.1, 2.0, 2.5 μg/mL, respectively), while 25, 26, and 27 were even
less potent. These results indicate that the size, orientation, and electronic effect of groups at
C-4 are important to the activity. Perhaps even more importantly, certain substituents could
greatly affect the SK-BR-3/MCF-7 selectivity. Compounds 20-22 had approximately tenfold
ratios of SK-BR-3/MCF-7 selectivity. For the D-ring analogs (45-53), most showed similar
activity against SKBR-3 and MCF-7. An exception was 51, which showed moderate activity
against SK-BR-3 (ED50 2.1 μg/mL), but was completely inactive against MCF-7.
To further explore the selectivity, compounds with ED50 values less than 4 μg/mL, were further
examined against two additional breast cancer cell lines, ZR-75-1 (ER+, HER2+) and MDA-
MB-231 (ER−). Most compounds had similar potency against the SK-BR-3 and ZR-75-1 cell
lines. However, 19 had a tenfold ratio of ZR-75-1/SK-BR-3 selectivity, while 20 had a threefold
ratio. Importantly, 21 showed a 23-fold ratio of ZR-75-1/MCF-7 selectivity. All tested
compounds were not active against the MDA-MB-231 cell line, which confirmed that these
novel analogs were highly selective.
As indicated by ZR-75-1/SK-BR-3 selectivity ratios, we observed that some compounds (e.g.,
20 and 21) were more sensitive to cell lines over-expressing only HER2 (SK-BR-3 and
ZR-75-1), while others (e.g., 19) were more sensitive to cell lines over-expressing both HER2
and ER (ZR-75-1). These results will facilitate our studies on the mechanism(s) of action.
Because ring-A is critical to activity and selectivity, we will further explore C1-C4 positions
in the future. We also investigated analogs involving skeletal modifications in ring-B, -C, or
–D. Compounds 32-33 contain a pyridinone rather than phenyl ring-B and were much less
active than 3. Bioisosteric modifications of either lactone oxygen to nitrogen or sulfur in ring-
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C led to dramatically decreased or abolished anti-breast cancer activity (38-39, 40-42). The
results demonstrated that the lactone ring is an important feature to the activity. Compounds
54 and 55 with a dihydrofuran ring-D showed decreased activity compared with 3 and 2,
respectively. Compound 58 with a substituted phenyl rather than furan D-ring was inactive.
These results, together with our previously reported data, indicated that an unsaturated furan
is favored for ring-D. Studies on different ring systems, such as 59 and 60, are also ongoing
(Figure 2).
To further investigate human tumor-tissue-type selectivity, compounds with ED50 values less
than 4 μg/mL against breast cancer cell lines were tested against four different human cancer
cell lines, A549 (lung), DU145 (prostate), KB (nasopharnygeal) and KB-vin (its vincristine-
resistant subline) using 2 as a positive control (Table 2). All compounds, except 22, were not
active against these four tumor cell lines. These results demonstrated that our novel analogs
were extremely selective for breast cancer cell lines.
Compound 2 was tested independently against cell lines derived from normal breast tissue
(MCF10A and 184A1) versus SK-BR-3 as a positive breast cancer cell line control, and results
are shown in Figure 3. The interpolated ED50 values are 0.1, 4.4, and 2.7 μg/mL against SK-
BR-3, 184A1 and MCF10A cells, respectively, showing that 2 is selective for a sub-set of
breast cancer-derived cell lines and is significantly less active against normal breast-derived
tissue.
We have examined the anti-cancer activity of compound 2 in several xenograft models, such
as PC-3 (androgen-independent human prostate carcinoma cells), MDA-MB-231 (estrogen
receptor negative basal-like breast cancer cells), and ZR-75-1 (estrogen receptor positive HER2
over-expressing breast cancer cells). Compound 2 was administered intraperitoneally (i.p.) in
a 4% benzyl alcohol/6% cremophor/90% D5W solution, and was given at 10 mg/kg every other
day to endpoint (qod to end). A positive reference group received paclitaxel i.p. at 20 mg/kg
every fourth day for 5 doses (q4d × 5). A control group received vehicle i.p. on a qod to end
schedule. As shown in Figure 4, the treatment of SCID mice with 2 resulted in inhibition of
estrogen-positive ZR-75-1 tumor xenograft growth. There was significant reduction in growth
of estrogen-positive breast tumors in 2-treated animals as compared with the control group.
Treatment results were presented as percent tumor growth delay (%TGD), which is the percent
increase in the mean time to endpoint (TTE) for drug-treated versus control mice. Logrank
tests determine significance of the differences between TTE values for compound 2-treated
and control mice, at P ≤ 0.05. In ZR-75-1 xenograft model, the mean TTE for the control group
was 15.1 days. Paclitaxel produced a mean TTE of 35.0 days, corresponding to a %TGD of
132. Compound 2 at 10 mg/kg produced a mean TTE of 29.5 days, corresponding to a %TGD
of 95 (p = 0.0067, logrank). Of the xenografts studied, treatment with 2 only suppressed
estrogen-dependent breast cancer, but had no effect on PC-3 (androgen-independent human
prostate carcinoma cells) or MDA-MB-231 (estrogen receptor negative basal-like breast cancer
cells). These findings suggest that compound 2 may be selectively used to inhibit the growth
of hormone-dependent breast cancers, particularly re-growth of residual tumor in
postmenopausal breast cancer survivors receiving estrogen and progesterone replacement
therapy.
Conclusions
In summary, a highly efficient synthesis of 2 was accomplished with fewer steps and higher
overall yield than those previously reported. This synthetic pathway was used to prepare new
analogs. The SAR study led to the following observations. (1) C-4 position is critical for both
potency and selectivity. The order of potency against SK-BR-3 was ethyl = 2-bromoethyl =
propyl > methyl = methoxy > fluoro = hydrogen > isopropyl > ethoxy > dimethylamino >
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acetate > hydroxyl. Analogs with 4-isopropyl, -propyl and -methoxy groups showed high
selectivity against different breast cancer cell lines. (2) The order of potency at the C-17
position was methyl > ethyl > hydrogen, while the order of potency at the C-16 position was
hydrogen > methyl. (3) Pyridinone ring is not favored for ring-B. (4) Lactone ring-C is essential
for activity; analogs with thiolactone and lactam rings were inactive or less active. (5) Ring-
D is preferably an unsaturated furan ring. Based upon all results, a mechanism of action study
is in progress. Due to their high selectivity and potency, 19-21 and 24 are novel promising anti-
breast cancer candidates. In addition, analog 2 showed potent activity against a ZR-75-1
xenograft model, but not PC-3 and MDA-MB-231 xenografts. Resistance to endocrine therapy
is an important issue in the management of HER2 over-expressing estrogen receptor-positive
breast cancer.23 Studies will continue to further establish the suitability of neo-tanshinlactone
analogs as clinical trials candidates for treating breast cancer.
Experimental Section
Materials and Methods
Melting points were measured with a Fisher Johns melting apparatus without correction. 1H
NMR spectra were measured on a 300 MHz Varian Gemini 2000 spectrometer using TMS as
internal standard. The solvent used was CDCl3 unless indicated. Mass spectra were measured
on a Shimadzu LC-MS2010 instrument. Thin-layer chromatography (TLC) and preparative
TLC were performed on precoated silica gel GF plates purchased from Merck, Inc. Biotage
Flash+ or Isco Companion systems were used for flash chromatography. Silica gel (200-400
mesh) from Aldrich, Inc., was used for column chromatography. All other chemicals were
obtained from Aldrich, Inc, and Fisher, Inc. Intermediates 7-18 and 36-37 for target compounds
19-23 and 38-39 were prepared by the optimized methods described in our previous and this
paper.13 Intermediates 30-31 were prepared by the reported method.24, 25 All final compounds
are >95% pure on the basis of two HPLC conditions.
Cell Growth Inhibition Assay
All stock cultures are grown in T-25 flasks. Freshly trypsinized cell suspensions were seeded
in 96-well microtiter plates with compounds added from DMSO-diluted stock. The plates were
incubated for an additional 72 h after attachment and drug addition, and the assay was
terminated by 10% TCA. Then, 0.4% SRB dye in 1% HOAc was added to stain the cells for
10 min. Unbound dye was removed by repeated washing with 1% HOAc and the plates were
air dried. Bound stain was subsequently solved with 10 mM trizma base, and the absorbance
read at 515 nm. Growth inhibition of 50% (ED50) was calculated as the drug concentration that
caused a 50% reduction in the net protein increase in control cells during the drug incubation.
The mean ED50 is the concentration of agent that reduces cell growth by 50% under the
experimental conditions and is the average from at least three independent determinations.
Variation between replicates was no more than 5% of the mean. The following human tumor
cell lines were used in the assay: A549 (non-small cell lung cancer), MCF-7 (estrogen receptor
positive luminal-like breast cancer), MDA MB-231 (estrogen receptor negative basal-like
breast cancer), SK-BR-3 (estrogen receptor negative, HER2 over-expressing luminal-like
breast cancer), ZR-75-1 (estrogen receptor positive breast cancer, HER2 over-expressing
luminal-like breast cancer), KB (nasopharyngeal carcinoma), KB-vin (vincristine-resistant KB
subline). All cell lines were obtained from the Lineberger Cancer Center (UNC-CH) or from
ATCC (Rockville, MD). Cells propagated in RPMI-1640 supplemented with 10% FBS,
Penicillin-100 IU/mL, Streptomycin-1μg/mL, Amphotericin B-0.25μg/mL, and were cultured
at 37°C in a humidified atmosphere of 95% air/5% CO2.
Optimized synthetic procedure to analog 2—To a solution of EtMgCl (3.0 M in diethyl
ether, 26 mL, 78 mmol), ZnCl2 (798 mg, 6 mmol) was added at rt under argon atmosphere.
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This mixture was stirred at rt for 1 h. Then, the solution was cooled to 0 °C, and 5-methoxy-1-
tetralone 4 (10.56 g, 60 mmol) was added at 0 °C. The mixture was stirred overnight. The
reaction mixture was quenched by saturated aqueous NH4Cl, extracted with EtOAc, and dried
over Na2SO4. The organic phase was concentrated under reduced pressure and the resulting
residue was purified by silica gel column chromatography (eluent: hexane/EtOAc), to give the
desired product 5 (10.5g, 85% yield). 10% Pd/C (7.18 g. 33.24 mmol) was added to a solution
of 5 (7.18g) in triglyme (15 mL), and the mixture was heated to reflux for 3 days to afford 6
(3.71 g, 60% yield). To a solution of 6 (3.5 g, 18.8 mmol) in anhydrous CH2Cl2 (20 mL) was
added a solution of boron tribromide in CH2Cl2 (1.0 M, 56.5 mL, 56.5 mmol) dropwise at 0 °
C. The mixture was stirred overnight at rt to give the desired naphthol intermediate 7 (3.07 g,
yield 95%) after silica gel chromatography. A mixture of 7 (2.14 g, 12.47 mmol), malonic acid
(1.43 g, 13.72 mmol), and PPA (85%P2O5, 20 g) was heated at 75 °C for 3 h. After cooling,
ice-water was added to the black residue. The mixture was filtered, and the solid dissolved in
MeOH. The organic layer was concentrated and purified with flash chromatography, eluting
with CH2Cl2:MeOH=10:1, to yield 13 as a yellow solid (1.52g, 53% yield). To a solution of
13 (440 mg, 1.83 mmol) in toluene (55 mL) was added a mixture of HOAc (549 mg, 9.15
mmol) and NH4OAc (704 mg, 9.15 mmol) in EtOH (16 mL) and chloroacetone (842 mg, 9.15
mmol). The mixture was stirred for 30 min at rt, and then heated to 60 °C for 30 min.
Subsequently, it was refluxed for 24 h. After cooling, the mixture was diluted with H2O and
extracted with EtOAc. The organic layer was dried over Na2SO4, filtered, and evaporated. The
residue was purified by column chromatography (hexane/EtOAc) to give 2 (356 mg, 70%
yield).
Synthesis of neo-tanshinlactone analogs 19-23, 32-33, 38-39, and 45-53—To a
solution of 13-18, or 30-31, or 36-37, or 43-44 (0.20 mmol) in toluene (8 mL) was added a
mixture of HOAc (59 mg, 1.0 mmol) and NH4OAc (75 mg, 1.0 mmol) in EtOH (2 mL) and
chloroacetone (90 mg, 1.0 mmol) or 3-bromobutan-2-one, 2-bromopropanal, 1-bromobutan-2-
one, 2-bromo-1-(4-methoxyphenyl)ethanone. The mixture was stirred for 30 min at rt, and then
heated to 60 °C for 30 min. Subsequently, it was refluxed for 24 h. After cooling, the mixture
was diluted with H2O and extracted with EtOAc. The organic layer was dried over Na2SO4,
filtered, and evaporated. The residue was purified by column chromatography (hexane/EtOAc)
to give a white solid.
6-Isopropyl-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (19)—65% yield;
mp 155-157 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.42 (t, J = 6.6 Hz, 6H, (CH3)2), 2.41
(d, J = 1.2 Hz, 3H, CH3), 3.76 (h, J = 6.9 Hz, 1H, CH(CH3)2), 7.44 (d, J = 1.2 Hz, 1H,
OCH), 7.56-7.64 (m, 2H, aromatic), 7.87 (d, J = 9.0 Hz, 1H, aromatic), 8.05 (d, J = 9.0 Hz,
1H, aromatic), 8.51 (d, J = 7.8 Hz, 1H, aromatic); HRMS for (M++H): calcd. 293.1178, found:
293.1168.
1-Methyl-6-propyl-11H-benzo[h]furo[3,2-c]chromen-11-one (20)—59% yield; mp
141-143 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.04 (t, J = 7.2 Hz, 3H, CH2CH2CH3), 1.78
(m, 2H, CH2CH2CH3), 2.40 (d, J = 1.2 Hz, 3H, CH3), 3.06 (t, J = 7.5 Hz, 2H, CH2CH2CH3),
7.42-7.46 (m, 2H, aromatic & OCH), 7.55 (t, J = 8.4 Hz, 1H, aromatic), 7.83 (d, J = 9.0 Hz,
1H, aromatic), 7.94 (d, J = 9.0 Hz, 1H, aromatic), 8.49 (d, J = 8.4 Hz, 1H, aromatic); HRMS
for (M++H): calcd. 293.1178, found: 293.1175.
6-Methoxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (21)—29% yield;
mp 225-227 °C ; 1H NMR (300 MHz, CDCl3, ppm): δ 2.40 (s, 3H, CH3), 4.02 (s, 3H,
OCH3), 6.95 (d, J = 7.8 Hz, 1H, aromatic), 7.42 (s, 1H, OCH), 7.54 (t, J = 7.8 Hz, 1H, aromatic),
7.78 (d, J = 9.0 Hz, 1H, aromatic), 8.15 (d, J = 9.0 Hz, 2H, aromatic); HRMS for (M++H):
calcd. 281.0814, found: 281.0816.
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6-Ethoxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (22)—28% yield; mp
201-203 °C 1H NMR (300 MHz, CDCl3, ppm): δ 1.56 (t, J = 7.2 Hz, 3H, CH2CH3), 2.39 (s,
3H, CH3), 4.20 (q, J = 7.2 Hz, 2H, CH2CH3), 6.91 (d, J = 7.8 Hz, 1H, aromatic), 7.40 (s, 1H,
OCH), 7.50 (t, J = 8.4 Hz, 1H, aromatic), 7.75 (d, J = 9.0 Hz, 1H, aromatic), 8.11 (d, J = 8.4
Hz, 1H, aromatic), 8.16 (d, J = 9.0 Hz, 1H, aromatic); HRMS for (M++H): calcd. 295.0970,
found: 295.0970.
6-Fluoro-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (23)—20% yield; mp
215-217 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.42 (d, J = 1.8 Hz, 3H, CH3), 7.27-7.33
(m, 1H, aromatic), 7.48 (d, J = 1.2 Hz, 1H, OCH), 7.55-7.62 (m, 1H, aromatic), 7.93 (d, J =
9.0 Hz, 1H, aromatic), 8.03 (d, J = 9.0 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H, aromatic); HRMS for
(M++H): calcd. 269.0614, found: 269.0616.
5-Aza-N-methyl-1-methyl-4H-benzo[h]furo[3,2,c]chromene-4,11-dione (32)—
50% yield; mp 265-267 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.38 (d, J = 1.5 Hz, 3H,
CH3), 3.82 (s, 3H, NCH3), 7.39 (t, J = 8.1 Hz, 1H, aromatic), 7.46 (d, J = 8.4 Hz, 1H, aromatic),
7.54 (d, J = 1.5 Hz, 1H, OCH), 7.68-7.74 (m, 1H, aromatic), 8.36 (dd, J = 1.2, 8.4 Hz, 1H,
aromatic); HRMS for (M++H): calcd. 282.0766, found: 282.0757.
5-Aza-N-propyl-1-methyl-4H-benzo[h]furo[3,2,c]chromene-4,11-dione (33)—
55% yield; mp 238-240 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.08 (t, J = 7.5 Hz, 3H,
CH2CH2CH3), 1.83 (h, J = 7.5 Hz, 2H, CH2CH2CH3), 2.38 (d, J = 0.9 Hz, 3H, CH3), 4.35 (t,
J = 7.5 Hz, 2H, CH2CH2CH3), 7.37 (t, J = 7.8 Hz, 1H, aromatic), 7.43 (d, J = 8.7 Hz, 1H,
aromatic), 7.53 (d, J = 1.2 Hz, 1H, OCH), 7.66-7.72 (m, 1H, aromatic), 8.35 (dd, J = 1.8, 7.8
Hz, 1H, aromatic); HRMS for (M++H): calcd. 310.1079, found: 310.1068.
1-Methyl-11H-benzo[h]furo[3,2-c]thiochromen-11-one (38)—8% yield; mp 137-139
°C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.42 (d, J = 1.5 Hz, 3H, CH3), 7.44 (q, J = 1.5 Hz,
1H, OCH), 7.61-7.64 (m, 2H, aromatic), 7.85 (d, J = 8.4 Hz, 1H, aromatic), 7.88-7.92 (m, 1H,
aromatic), 8.15 (d, J = 8.7 Hz, 1H, aromatic), 8.21-8.22 (m ,1H, aromatic); HRMS for
(M++H): calcd. 267.0480, found: 267.0473.
1-Methylbenzo[h]furo[3,2-c]quinolin-11(10H)-one (39)—10% yield; mp 135-137 °
C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (d, J = 1.5 Hz, 3H, CH3), 7.47 (d, J = 1.2 Hz,
1H, OCH), 7.61-7.71 (m, 3H, aromatic), 7.93 (d, J = 8.4 Hz, 1H, aromatic), 7.98 (d, J = 8.7
Hz, 1H, aromatic), 8.45 (d, J = 8.1 Hz, 1H, aromatic); HRMS for (M++H): calcd. 250.0868,
found: 250.0855.
1-Ethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (45)—64% yield; mp 151-153 °
C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.32 (t, J = 7.5 Hz, 3H, CH2CH3), 2.78 (q, J = 7.5 Hz,
2H, CH2CH3), 7.32 (s, 1H, OCH), 7.52-7.61 (m, 3H, aromatic), 7.66 (d, J = 8.4 Hz, 1H,
aromatic), 7.76 (d, J = 8.7 Hz, 1H, aromatic), 8.43 (d, J = 7.5 Hz, 1H, aromatic); HRMS for
(M++H): calcd. 265.0865, found: 265.0865.
1-Ethyl-6-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (46)—65% yield; mp
183-185 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.33 (q, J = 7.5 Hz, 3H, CH2CH3), 2.65 (s,
3H, CH3), 2.81 (q, J = 7.2 Hz, 2H, CH2CH3), 7.37 (s, 2H, aromatic & OCH), 7.45 (t, J = 8.1
Hz, 1H, aromatic), 7.71 (d, J = 8.7 Hz, 1H, aromatic), 7.78 (d, J = 9.0 Hz, 1H, aromatic), 8.36
(d, J = 8.4 Hz, 1H, aromatic); HRMS for (M++H): calcd. 279.1021, found: 279.1017.
1,6-Diethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (47)—75% yield; mp 101-103
°C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.33 (q, J = 7.8 Hz, 6H, CH3), 2.83 (q, J = 7.5 Hz,
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2H, CH2CH3), 3.04 (q, J = 7.8 Hz, 2H, CH2CH3), 7.35-7.40 (m, 2H, aromatic & OCH), 7.48
(t, J = 7.5 Hz, 1H, aromatic), 7.70 (d, J = 9.3 Hz, 1H, aromatic), 7.83 (d, J = 8.7 Hz, 1H,
aromatic), 8.37 (d, J = 8.1 Hz, 1H, aromatic); HRMS for (M++H): calcd. 293.1178, found:
293.1169.
1,2-Dimethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (48)—15% yield; mp
103-105 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.32 (d, J = 0.9 Hz, 3H, OCCH3), 2.42 (d,
J = 0.9 Hz, 3H, CH3), 7.59-7.65 (m, 2H, aromatic), 7.72 (d, J = 8.7 Hz, 1H, aromatic), 7.82
(d, J = 8.7 Hz, 1H, aromatic), 7.85-7.88 (m, 1H, aromatic), 8.58 (d, J = 8.7 Hz, 1H, aromatic);
HRMS for (M++H): calcd. 265.0865, found: 265.0860.
6-Ethyl-1,2-dimethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (49)—29% yield;
mp 141-143 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.29
(s, 3H, OCCH3), 2.39(s, 3H, CH3), 3.09 (q, J = 7.5 Hz, 2H, CH2CH3), 7.42 (d, J = 6.9 Hz, 1H,
aromatic), 7.50-7.55 (m, 1H, aromatic), 7.75-7.80 (m, 1H, aromatic), 7.88-7.91 (m, 1H,
aromatic), 8.44 (d, J = 8.1 Hz, 1H, aromatic); HRMS for (M++H): calcd. 293.1178, found:
293.1172.
2-Methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (50)—12% yield; mp 229-231 °
C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (s, 3H, CH3), 6.63 (s, 1H, OCCH), 7.61-7.65 (m,
2H, aromatic), 7.75 (d, J = 8.7 Hz, 1H, aromatic), 7.83-7.90 (m, 2H, aromatic), 8.59 (d, J =
7.5 Hz, 1H, aromatic); HRMS for (M++H): calcd. 251.0708, found: 251.0703.
6-Ethyl-2-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (51)—2% yield; mp
175-177 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.41 (t, J = 7.5 Hz, 3H, CH2CH3), 2.54 (s,
3H, CH3), 3.15 (q, J = 7.5 Hz, 2H, CH2CH3), 6.64 (s, 1H, OCCH), 7.48 (d, J = 7.2 Hz, 1H,
aromatic), 7.58 (t, J = 7.2 Hz, 1H, aromatic), 7.88 (d, J = 9.0 Hz, 1H, aromatic), 8.00 (d, J =
9.0 Hz, 1H, aromatic), 8.50 (d, J = 8.4 Hz, 1H, aromatic); HRMS for (M++H): calcd. 279.1021,
found: 279.1017.
1-(4-Methoxyphenyl)-11H-benzo[h]furo[3,2-c]chromen-11-one (52)—20% yield;
mp 173-175 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 3.88 (s, 3H, CH3), 7.02 (d, J = 9.0 Hz,
2H, aromatic), 7.64-7.68 (m, 2H, aromatic & OCH), 7.59-7.80 (m, 4H, aromatic), 7.90-7.94
(m, 2H, aromatic), 8.62-8.65 (m, 1H, aromatic); HRMS for (M++H): calcd. 343.0970, found:
343.0975.
6-Ethyl-1-(4-methoxyphenyl)-11H-benzo[h]furo[3,2-c]chromen-11-one (53)—
34% yield; mp 185-187 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.5 Hz, 3H,
CH2CH3), 3.11 (q, J = 7.2 Hz, 2H, CH2CH3), 3.86 (s, 3H, OCH3), 6.85-7.01 (m, 2H, aromatic),
7.46 (d, J = 6.6 Hz, 1H, aromatic), 7.56 (t, J = 7.8 Hz, 1H, aromatic), 7.72-7.77 (m, 3H, aromatic
& OCH), 7.86 (d, J = 8.7 Hz, 1H, aromatic), 7.95 (d, J = 8.7 Hz, 1H, aromatic), 8.47 (d, J =
8.1 Hz, 1H, aromatic); HRMS for (M++H): calcd. 371.1283, found: 371.1291.
6-(1-Bromoethyl)-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (24)—To a
solution of 2 (27 mg, 0.1 mmol) in CCl4 (3 mL) was added N-bromosuccinimide (18 mg, 0.1
mmol) and dibenzoyl peroxide (2 mg). The reaction mixture was stirred and heated at reflux
for 9 h. After the mixture was cooled in an ice bath, the solid was removed by filtration and
washed with CCl4. Concentration and silica gel flash column chromatography (hexane-EtOAc,
8:1) gave 24 (18 mg, 52%) as a white solid.
52% yield; mp 173-175 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.29 (d, J = 6.9 Hz, 3H,
CHBrCH3), 2.42 (d, J = 1.2 Hz, 3H, CH3), 5.97 (q, J = 7.5 Hz, 1H, CHCH3), 7.47 (d, J = 1.2
Hz, 1H, OCH), 7.65 (t, J = 7.8 Hz, 1H, aromatic), 7.88 (d, J = 6.9 Hz, 1H, aromatic), 8.00 (d,
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J = 9.0 Hz, 1H, aromatic), 8.15 (d, J = 8.7 Hz, 1H, aromatic), 8.65 (d, J = 8.7 Hz, 1H, aromatic);
HRMS for (M++H): calcd. 357.0126, found: 357.0120.
6-Hydroxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (25)—To a solution
of 21 (32 mg, 0.114 mmol) in DCM (3 ml) was added BBr3 (1.12 mL, 1.12 mmol) dropwise
at 0 °C. The reaction mixture was stirred and warmed to rt for 12 h. Water was added to quench
the reaction. The solution was extracted with CHCl3. The organic layer was concentrated
purified with flash chromatography, eluting with DCM-MeOH, 15:1, to give 25.
52% yield; 1H NMR (300 MHz, DMSO, ppm): δ 2.30 (s, 3H, CH3), 7.06 (d, J = 8.7 Hz, 1H,
aromatic), 7.53 (t, J = 8.4 Hz, 1H, aromatic), 7.82-7.86 (m, 2H, aromatic), 7.97 (d, J = 1.2 Hz,
1H, OCH), 8.11 (d, J = 9.3 Hz, 1H, aromatic), 10.58 (s, 1H, OH); HRMS for (M+-H): calcd.
265.0501, found: 265.0505.
1-Methyl-11-oxo-11H-benzo[h]furo[3,2-c]chromen-6-yl acetate (26)—Compound
25 (0.1 mmol) was dissolved in acetic anhydride under argon. Triethylamine (0.14 mL, 1.0
mmol) was added to the solution. After stirring overnight at 60 °C, the solution was washed
with water and extracted with DCM, and dried (MgSO4). Removal of solvent under reduced
pressure yielded a white solid, which was purified by column chromatography, eluting with
EtOAc–hexane (1:4).
43% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, CH3), 2.50 (s, 3H, COCH3), 7.39
(d, J = 6.9 Hz, 1H, aromatic), 7.46 (s, 1H, OCH), 7.65 (t, J = 8.1 Hz, 1H, aromatic), 7.80 (d,
J = 8.7 Hz, 1H, aromatic), 7.90 (d, J = 8.7 Hz, 1H, aromatic), 8.52 (d, J = 8.4 Hz, 1H, aromatic);
HRMS for (M++H): calcd. 309.0763, found: 309.0762.
6-(2-(Dimethylamino)ethoxy)-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-
one (27)—Compound 25 (0.1 mmol) was dissolved in acetone under argon. K2CO3 (235 mg,
1.7 mmol) was added to the solution. After stirring for 10 min, 2-chloro-N,N-
dimethylethylamine hydrochloride (30 mg, 0.2 mmol) was added to the mixture. After
refluxing for 10 h, the mixture was filtrated and concentrated. The residue was purified by
column chromatography, eluting with EtOAc–hexane (1:2).
9% yield; mp 209-211 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, CH3), 2.44 (s,
6H, N(CH3)2), 2.96 (t, J = 5.1 Hz, 2H, OCH2CH2), 4.31 (t, J = 5.1 Hz, 2H, OCH2CH2), 6.98
(d, J = 7.5 Hz, 1H, aromatic), 7.45 (s, 1H, OCH), 7.55 (t, J = 8.1 Hz, 1H, aromatic), 7.83 (d,
J = 8.7 Hz, 1H, aromatic), 8.20 (dd, J = 7.2, 8.7 Hz, 2H, aromatic); HRMS for (M++H): calcd.
338.1392, found: 338.1389.
Synthesis of neo-tanshinlactone analogs 40-41—A mixture of compound 3 or 2 (0.1
mmol) and Lawesson's reagent (81 mg, 0.2 mmol) in dry toluene (5 mL) was heated to reflux
for 7 h. After cooling, toluene was removed in vacuo, and the red residue was dissolved in
EtOAc and partitioned with H2O. The organic phase was separated and dried over MgSO4.
Removal of solvent in vacuo afforded an oily residue, which was purified by column
chromatography (EtOAc-hexane) to give a yellow solid.
1-Methyl-11H-benzo[h]furo[3,2-c]chromene-11-thione (40)—90% yield; mp
267-269 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (s, 3H, CH3), 7.46 (s, 1H, OCH),
7.67-7.69 (m, 2H, aromatic), 7.79-7.92 (m, 3H, aromatic), 8.75 (d, J = 7.2 Hz, 1H, aromatic);
HRMS for (M++H): calcd. 267.0480, found: 267.0471.
6-Ethyl-1-methyl-11H-benzo[h]furo[3,2-c]chromene-11-thione (41)—84% yield;
mp 189-191 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.49
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(d, J = 1.2 Hz, 3H, CH3), 3.09 (q, J = 7.5 Hz, 2H, CH2CH3), 7.40 (d, J = 1.5 Hz, 1H, OCH),
7.46 (d, J = 7.2 Hz, 1H, aromatic), 7.56 (t, J = 7.2, 8.1 Hz, 1H, aromatic), 7.78 (d, J = 9.0 Hz,
1H, aromatic), 7.95 (d, J = 9.0 Hz, 1H, aromatic), 8.55 (d, J = 8.7 Hz, 1H, aromatic); HRMS
for (M++H): calcd. 295.0793, found: 295.0779.
6-Ethyl-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one oxime (42)—A mixture
of 41 (22 mg. 0.075 mmol), hydroxylamine hydrochloride (10.4 mg, 0.15 mmol), sodium
acetate (12 mg, 0.15 mmol), and MeOH (5 mL) was refluxed overnight and then filtered. The
filtrate was concentrated under reduced pressure to give an oil. Purification by the column
chromatography (EtOAc–hexane) on silica gel gave 42 as a white in 87% yield.
89% yield; mp 211-213 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.2 Hz, 3H,
CH2CH3), 2.28 (d, J = 0.9 Hz, 3H, CH3), 3.11 (q, J = 7.5 Hz, 2H, CH2CH3), 7.18 (s, 1H,
OH), 7.33 (d, J = 1.2 Hz, 1H, OCH), 7.40 (d, J = 6.9 Hz, 1H, aromatic), 7.52 (dd, J = 7.2, 8.4
Hz, 1H, aromatic), 7.71 (d, J = 9.0 Hz, 1H, aromatic), 7.86 (d, J = 9.0 Hz, 1H, aromatic), 8.40
(d, J = 8.7 Hz, 1H, aromatic); HRMS for (M++H): calcd. 294.1130, found: 294.1118.
Synthesis of neo-tanshinlactone analogs 54-55—Compound 3 or 2 (0.2 mmol) was
dissolved in acetone at 40 °C under argon. Pd/C (81 mg, 10%), triethylamine (0.33 mL, 2.40
mmol) and formic acid (0.075 mL, 2.00 mmol) were added to the solution. After stirring
overnight, TLC showed some substrate remained unreacted. The solution was filtered through
Celite and solvent removed in vacuo to yield a dark oil. The residue was dissolved in DCM
before washing with saturated aqueous sodium bicarbonate (5 mL), aqueous citric acid (5 mL,
10% v/v), water (5 mL) and brine (5 mL), and then dried (MgSO4). Removal of solvent under
reduced pressure yielded a white solid, which was purified by column chromatography, eluting
with EtOAc–hexane (1:4).
1-Methyl-1H-benzo[h]furo[3,2-c]chromen-11(2H)-one (54)—30% recovered yield;
mp 143-145 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.46 (d, J = 6.9 Hz, 3H, CHCH3),
3.68-3.77 (m, 1H, CHCH3), 4.47 (q, J = 6.3 Hz, 1H, CH2), 5.00 (t, J = 6.6 Hz, 1H, CH2),
7.62-7.71 (m, 4H, aromatic), 7.87-7.90 (m, 1H, aromatic), 8.59-8.62 (m, 1H, aromatic); HRMS
for (M++H): calcd. 253.0865, found: 253.0856.
6-Ethyl-1-methyl-1H-benzo[h]furo[3,2-c]chromen-11(2H)-one (55)—56%
recovered yield; mp 83-85 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.8 Hz, 3H,
CH2CH3), 1.46 (d, J = 7.5 Hz, 3H, CHCH3), 3.13 (q, J = 7.5 Hz, 2H, CH2CH3), 3.66-3.78 (m,
1H, CHCH3), 4.47 (q, J = 6.0 Hz, 1H, CH2), 5.00 (t, J = 6.6 Hz, 1H, CH2), 7.50-7.60 (m, 2H,
aromatic), 7.64 (d, J = 9.3 Hz, 1H, aromatic), 7.91 (d, J = 9.3 Hz, 1H, aromatic), 8.49 (d, J =
8.7 Hz, 1H, aromatic); HRMS for (M++H): calcd. 281.1178, found: 281.1163.
Naphthalen-1-yl 2-bromo-4-methylbenzoate (57)—Thionyl chloride (0.17ml, 2.40
mmol) was added to 2-bromo-4-methylbenzoic acid (430 mg, 2 mmol) in DCM (3 mL) and
DMF (0.1 mL), and the mixture was refluxed under nitrogen atmosphere for 1 h. After cooling
to rt, it was concentrated in vacuo to give the title compound as a pale yellow solid, which was
used directly in the next step.
Naphthalen-1-ol (288 mg, 2.00 mmol) was dissolved in THF (5 mL), then DMAP (5 mg) and
ethyldiisopropylamine (0.36 mL, 2.05 mmol) were added, and the mixture was cooled to 0 °
C for 10 min. Freshly prepared 2-bromo-4-methylbenzoyl chloride in dry THF (10 mL) was
added to the mixture via cannula, and the resulting mixture was stirred at 25 °C for 2 h, diluted
with diethyl ether (150 mL), and quenched by the addition of water (15 mL). The organic layer
was washed with HCl and NaHCO3 and then dried (Na2SO4) and concentrated in vacuo. The
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residue was purified with flash chromatography, eluting with hexane: EtOAc=10:1, to give
57.
96% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, CH3), 7.27 (dd, J = 0.9, 8.1 Hz,
1H, aromatic), 7.40 (dd, J = 1.2, 7.5 Hz, 1H, aromatic), 7.48-7.52 (m, 3H, aromatic), 7.60 (d,
J = 0.9 Hz, 1H, aromatic), 7.77 (d, J = 8.1 Hz, 1H, aromatic), 7.87-7.90 (m, 1H, aromatic),
7.96-7.99 (m, 1H, aromatic), 8.13 (d, J = 8.1 Hz, 1H, aromatic).
9-Methyl-6H-dibenzo[c,h]chromen-6-one (58)—A mixture of 57 (68 mg, 0.2 mmol),
PdCl(OAc)2 (4.5 mg, 0.02 mmol), PPh3 (10.5 mg, 0.04 mmol), and NaOAc (32.8 mg, 0.4
mmol) was dissolved in dry dimethylacetamide (10 mL), and the solution was degassed and
then heated to 150 °C for 3 h. On cooling to rt, the solution was diluted with diethyl ether (50
mL) and washed with HCl, and the ethereal extracts were dried over Na2SO4. The solution
was filtered, the filtrate condensed in vacuo, and the resulting oil purified by flash
chromatography (hexane:EtOAc 4:1) to give the title compound as a white solid.
65% yield; mp 193-195 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.55 (s, 3H, CH3), 7.35-7.38
(m, 1H, aromatic), 7.57-7.63 (m, 2H, aromatic), 7.71 (d, J = 9.0 Hz, 1H, aromatic), 7.82-7.85
(m, 1H, aromatic), 7.91 (s, 1H, aromatic), 8.00 (d, J = 9.3 Hz, 1H, aromatic), 8.30 (d, J = 7.8
Hz, 1H, aromatic), 8.53-8.56 (m, 1H, aromatic); HRMS for (M++H): calcd. 261.0916, found:
261.0909.
Methodology of MTT assay26—The MTT assay was used to access the in vitro anticancer
activity of 2 against two normal breast cancer cell lines 184A1 and MCF10A (CRL-10317)
purchased from ATCC (Rockville, MD) and using SK-BR-3 as a positive control. Cells were
seeded into 96 well plates at a density of 5000 cells per well in the recommended growth
medium. The drug was dissolved in DMSO. The drug was added into wells after overnight
incubation. After 72 h of incubation at 37 °C in 5% CO2, 20 μL of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5 -diphenyl tetrazolium bromide] reagent was added to each well and
incubated for two h. The amount of formazon product was measured at an OD of 570 nM using
a plate-reader.
Antitumor Activity in Vivo
Male (for PC-3) and female (for MDA-MB-231, and ZR-75-1) SCID mice (NTUH Animal
Facility) were 5 weeks old, and had a body weight (BW) range of 20-24 g, on D1 of the study.
The animals were fed ad libitum water (reverse osmosis, 1 ppm Cl) and PicoLab Rodent Diet
20 Modified and Irradiated Lab Diet® consisting of 20.0% crude protein, 9.9% crude fat, and
4.7% crude fiber. The mice were housed at National Taiwan University Laboratory Animal
Center, NTUMC, on a 12-hour light cycle at 21–23 °C and 60–85% humidity. Nude-athymic
mice were maintained in accordance with the Institutional Animal Care and Use Committee
procedures and guidelines. All human cancer cells were maintained in RPMI 1640 medium
containing 100 units/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, 0.25 μg/mL
amphotericin B, and 25 μg/mL gentamicin. The medium was supplemented with 10% heat-
inactivated fetal bovine serum and 2 mM glutamine. The cells were cultured in tissue culture
flasks in a humidified incubator at 37 °C, in an atmosphere of 5% CO2 and 95% air. All human
cancer cells used for implantation were harvested during log phase growth and resuspended in
phosphate-buffered saline at 5 × 107 cells/mL. Each mouse was injected s.c. in the right flank
with 1 × 107 cells (0.2 mL cell suspension). Tumors were monitored twice weekly and then
daily as their volumes approached 80-150 mm3. Tumor size, in mm3, was calculated from:
Tumor Volume = w2 × l / 2 where w = width and l = length in mm of the tumor. Tumor weight
can be estimated with the assumption that 1 mg is equivalent to 1 mm3 of tumor volume.
Treatment efficacy was determined from tumor growth delay (TGD), which is defined as the
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increase in the mean TTE (the time to endpoint) for a treatment group compared to the control
group:
expressed in days, or as a percentage of the mean TTE of the control group:
where T = mean TTE for a treatment group, C = mean TTE for control Group 1.
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Refer to Web version on PubMed Central for supplementary material.
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Structures of tamoxifen, neo-tanshinlactone (1) and its analogs 2-3
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Structures designed for future study
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Selective in vitro anticancer activity of 2 against SK-BR-3 breast cancer versus normal breast
tissue-derived cell lines (MCF10A and 184A1). Legend: Cell line description, source and
activity determination using the MTT-dye assay are described in the experimental section.
Graphical data are the mean and standard deviation of values obtained from replicates in a
single experiment.
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Figure 4. Anticancer activity of 2
The efficacy of 2 on the growth of human PC-3, MDA-MB-231, and ZR-75-1 xenografts in
SCID mice. Treatment with compound 2 selectively abrogated the hormone-dependent breast
cancer. Tumor growth is presented as the mean tumor volume (mm3) ± SE. Tumor volume
was determined by caliper measurements and was calculated as the product of 1/2 × length ×
width2. Each value represents the mean of at least five animals.
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Reagents and conditions: (a) EtMgBr, ZnCl2, THF, rt; (b) Pd/C, triglyme, reflux; (c) BBr3,
CH2Cl2; (d) malonic acid, PPA (85% P2O5), 75 °C, 3 h; (e) chloroacetone, HOAc/NH4OAc,
toluene/EtOH, reflux, 24 h; (f) NBS, dibenzoyl peroxide, toluene, reflux; (g) BBr3, CH2Cl2,
reflux, 3 h; (h) Ac2O, Et3N, 10 h; (i) 2-chloro-N,N-dimethylethanamine, K2CO3, acetone, 12h.
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Reagents and conditions: (a) diethyl malonate, 220°C, 8h; (b) chloroacetone, HOAc/NH4OAc,
toluene/EtOH, reflux, 24 h.
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Reagents and conditions: (a) malonic acid, PPA (85% P2O5), 75 °C, 3 h; (b) chloroacetone,
HOAc/NH4OAc, toluene, EtOH, reflux, 24 h; (c) diethyl malonate, PPA (85% P2O5), 170 °C,
2h; (d) Lawesson's reagent, toluene, reflux, 5h; (e) NH2OH HCl, NaOAc, MeOH, reflux, 12
h.
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Reagents and conditions: (a) HOAc/NH4OAc, toluene, EtOH, reflux, 24 h; (b) Et3N, formic
acid, Pd/C, acetone, 12 h; (c) 2-bromo-4-methylbenzoyl chloride, DMAP, DIEA, THF, rt, 12h;
(d) Pd(OAc)2, PPh3, NaOAc, DMF, reflux, 3h.
Dong et al. Page 22


























































































































































































































































































































































































































































































































































































































































































































Dong et al. Page 25
Table 2
Cytotoxicity of Compounds against Tumor Cell Linesa
Compd A549 DU145 KB KBvin
2 11 16 13 13
19 11 11 11 7.3
20 12 15 12 11
21 10 14 13 12
22 3.5 4.7 3.7 5.3
23 14 18 13 15
24 >20 18 13 >20
45 8.2 8.7 7.5 6.6
47 18 16 12 15
51 12 14 14 13
a
mean ED50 (μg/mL), from 2 or more independent tests (standard error is listed in supporting information).
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